Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study described trichilemmal cysts, firm lumps that form from blocked hair follicles, typically found on the scalp but also less commonly on other body parts, affecting less than 10% of the population and possibly inherited as an autosomal dominant trait.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

In this study, a 32-year-old female with alopecia areata experienced significant symptom relief after receiving traditional Ayurvedic treatments, including Virechana, Pracchana, and Rasayana therapies, alongside external application of Chakramarda. The protocol was reported to be simple, cost-effective, and highly efficacious.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

This study describes a 62-year-old male with trichodaganomania, an urge to bite his mustache hair, who was treated with counseling and placebo medication, highlighting the need for a comprehensive treatment approach including potential psychological and psychiatric interventions if symptoms recur.

This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This systematic review and meta-analysis found that bimatoprost, especially when used with NB-UVB phototherapy, FxCO2 laser, or mometasone, may be an effective and well-tolerated treatment option for vitiligo, achieving significant patient satisfaction and repigmentation, despite some limitations like small sample sizes and high costs.

This study reports a case where cyclosporine effectively treated a 51-year-old woman with idiopathic follicular mucinosis resistant to other therapies, suggesting its potential as an option for refractory cases.

This review reports that transgender patients undergoing hormone therapy may experience acne differently, necessitating tailored treatments that take into account skin dryness and the potential need for maintenance topical treatments.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This review found that various dermatological procedures for Seborrheic Dermatitis, such as phototherapy and laser treatments, showed significant efficacy in small cohorts with high patient satisfaction, but highlighted the need for further research to standardize protocols and evaluate long-term outcomes.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

This study found that sleep deprivation in mice can trigger prostatitis by activating the cGAS-STING pathway due to reduced levels of dihydrotestosterone and melatonin, resulting in a pro-inflammatory environment, while recovery sleep can mitigate these effects.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This case study reports that platelet-rich plasma treatment led to total hair regrowth in a 71-year-old woman with alopecia areata who had not responded to previous standard therapies.

Methylprednisolone treatment helps most alopecia areata patients, but young age, extensive hair loss, and low vitamin D can affect results.

Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.

This study found that acne tarda is prevalent, particularly among women and individuals with darker skin, with hormonal imbalances and endocrine disorders like PCOS commonly associated with its pathogenesis.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This study found that platelet-rich plasma, used as a sole treatment in male patients with androgenetic alopecia, may improve hair growth over a three-month period.

This case study reported significant improvement in autoimmune-related symptoms, including complete hair regrowth, in a patient with systemic lupus erythematosus and alopecia areata after treatment with the LGS Protocol.

This review discusses various types of hair loss associated with COVID-19 and vaccinations, highlighting acute telogen hair loss as the most common form, but reports no new clinical results.

This study concluded that the inferiorly based nasolabial flap is an effective and reliable option for reconstructing oral cavity defects in patients with oral submucous fibrosis, achieving significant improvements in mouth opening without serious complications.

This case study reports a new LAMB3 mutation linked to junctional epidermolysis bullosa with severe urinary tract stenosis, outlining treatment challenges and expanding knowledge of EB-related urological complications.